TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02916472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CyberCycling
Description: All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Bands
Description: Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins.
Study: NCT03122964

Intervention type: DIAGNOSTIC_TEST
Intervention: AssureMDx
Description: combined panel of methylation and mutation markers for the detection of bladder cancer
Study: NCT01340833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) \[14C\]GSK2118436, starting 1.75 hours after the oral dose
Study: NCT02742909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhBNP
Description: rhBNP was administered as a continuous infusion for 24 hours before or after placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline as a placebo was administered as a continuous infusion for 24 hours
Study: NCT02687919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Paleo diet
Description: Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
Study: NCT04400708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block
Description: After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of 0.5% ropivacaine 15ml is given.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control group
Description: After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of normal saline15ml is given.
Study: NCT03068286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space in Diabetes
Description: The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
Study: NCT03580304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Industrial work
Description: Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Industrial work
Description: Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Industrial work
Description: Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
Study: NCT03068286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space in COPD
Description: The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored.Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space in Chronic Pain
Description: The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain.
Study: NCT02999997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ronnie Gardiner Method (RGM)
Description: RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
Study: NCT01623427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of vacuum
Description: The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
Study: NCT04734041

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Anti-inflammatory (Mediterranean-style) diet
Description: Prescription of an anti-inflammatory diet, which encourages increasing whole fruits, vegetables, and grains, as well as balancing macronutrients (proteins, carbohydrates, and fat) for every meal.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral and psychosocial support
Description: Capture a complete and detailed medical history and background. Discuss familial and social support, provide psychosocial support, assess the patient's current self-management strategies for self-care, and assess the patient's current self-management strategies for mental health. Recommendations will be made in accordance with the needs of the participant.
Study: NCT00329303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (Cimzia®)
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~* Dose and Administration details :~  2 x 1 mL Certolizumab Pegol at Week 0, followed by~* 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~* 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (Cimzia®)
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~* Dose and Administration details :~  2 x 1 mL Certolizumab Pegol at Week 0, followed by~* 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~* 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10
Study: NCT01257165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Zopiclone pill 5 or 10 mg, given orally as a single dose.
Study: NCT03259542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 300 MG
Description: mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 MG
Description: itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
Study: NCT01623427

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No vacuum
Description: Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
Study: NCT03580304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Industrial work
Description: Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Industrial work
Description: Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Industrial work
Description: Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical load
Description: The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical load
Description: The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
Study: NCT03379584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD48A
Description: Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
Study: NCT02462057

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email message regarding the HealthyFood benefit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email message regarding the HealthyFood benefit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email message regarding the HealthyFood benefit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email message regarding the HealthyFood benefit
Study: NCT01070862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, Dexamethasone
Description: Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristin , Adriamycin, Dexamethasone = VAD
Description: Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)
Description: Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan, endoxan, dexamethasone (MCDex)
Description: melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, Dexamethasone
Description: Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
Study: NCT02567552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous progesterone
Description: subcutaneous progesterone 25 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular progesterone
Description: intramuscular progesterone 50 mg/day
Study: NCT02123628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duration of the antibiotic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duration of the antibiotic therapy
Study: NCT03302520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoMax, BioAlpha Inc, Seong-nam, Korea
Description: CaO-SiO2-P2O5-B2O3 glass ceramics spacer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK cage
Description: PEEK cage
Study: NCT05656989

Intervention type: OTHER
Intervention: Periodontal clinical measurements and GCF sampling
Description: Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.

Intervention type: OTHER
Intervention: Periodontal clinical measurements and GCF sampling
Description: Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.

Intervention type: OTHER
Intervention: Periodontal clinical measurements and GCF sampling
Description: Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
Study: NCT02168426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guardix
Description: Applying 6g of guardix during abdominal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guardix
Description: Applying 6g of guardix during abdominal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm
Description: Applying 1 sheet of seprafilm during abdominal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm
Description: Applying 1 sheet of seprafilm during abdominal surgery
Study: NCT00596180

Intervention type: DRUG
Intervention: HBOT
Description: total body exposure to greater than atmospheric pressure oxygen
Study: NCT03243266

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC/Diff Reference Interval
Description: Results will not be used to manage patients
Study: NCT04561674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of web-based patient education
Description: Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
Study: NCT02745067

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced cognitive behavioral therapy
Study: NCT03150667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor in patients with CKD presenting with ACS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel in patients with CKD presenting with ACS.
Study: NCT03206255

Intervention type: PROCEDURE
Intervention: 3 doses of HPV 16/18 bivalent vaccine
Description: Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)

Intervention type: PROCEDURE
Intervention: 3 doses of HPV 16/18 bivalent vaccine
Description: Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)

Intervention type: PROCEDURE
Intervention: 2 doses of HPV 16/18 bivalent vaccine
Description: Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
Study: NCT00003046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin-12
Description: Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
Study: NCT01152450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg b.i.d
Description: 2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: N/A (two actuations of placebo) delivered via Respimat® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg q.d.
Description: 5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
Study: NCT02841527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Band
Description: Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
Study: NCT04405804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine 5Mg Tab
Description: Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 2.5 mg/day in patients between 3-18 years with weight \> 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 15 mg/day in patients between 3-18 years, weight \> 40 kg
Study: NCT04146272

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Mermaid Current
Description: The current hearing aid used to treat hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Mermaid Current
Description: The current hearing aid used to treat hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Mermaid New
Description: The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Mermaid New
Description: The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.